drugset / Trial / NCT00360126

An Open-Label Extension Study Of Lamotrigine In Subjects With Bipolar Disorder

NCT00360126

Phase 4 Completed 11 enrolled GlaxoSmithKline
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The precursor study (SCA101469) was an open-label, prospective multicentre study in adult subjects diagnosed with bipolar disorder consisting of 36 weeks treatment with lamotrigine. The current study is to provide 12 months post study access to open-label lamotrigine for participants of the SCA101469 study.

Timeline

Start
2005-10
Primary completion
2007-02
Completion
2007-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Lamotrigine Small molecule

Indications